Shopping Cart
Remove All
Your shopping cart is currently empty
KRAS inhibitor-3, an efficacious inhibitor of both wild-type (WT) and oncogenic KRAS mutations, exhibits high-affinity binding (K D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS Q61H). Additionally, it impedes the interaction between KRAS and Raf, highlighting its potential as a targeted therapeutic agent in KRAS-mutant cancers.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $970 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,260 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,990 | 6-8 weeks | 6-8 weeks |
| Description | KRAS inhibitor-3, an efficacious inhibitor of both wild-type (WT) and oncogenic KRAS mutations, exhibits high-affinity binding (K D: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS Q61H). Additionally, it impedes the interaction between KRAS and Raf, highlighting its potential as a targeted therapeutic agent in KRAS-mutant cancers. |
| Targets&IC50 | KRas (Q61H):0.74 μM (EC50), KRas (G12C):0.63 μM (EC50), KRas (WT):0.28 μM (EC50), KRas (G12D):0.37 μM (EC50) |
| Molecular Weight | 413.51 |
| Formula | C25H27N5O |
| Cas No. | 900897-56-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.